A multicenter phase II trial of the applicability and safety of magnifying narrow-band imaging for diagnosis of histological type of early gastric cancer

A multicenter phase II trial of the applicability and safety of magnifying narrow-band imaging for diagnosis of histological type of early gastric cancer - A multicenter phase II trial of the applicability and safety of M-NBI for diagnosis of histological type of early gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032151

Enrollment

207

Registered

2018-04-08

Start date

2018-04-09

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Forceps biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1. Risk of bleeding after biopsy. 2. History of gastrectomy. 3. Macroscopically, the targeted lesion is elevated type. 4. The size of the targeted lesion is smaller than 5 mm. 5. Erosion or an ulcer in the center of the targeted lesion. 6. Informed consent was not obtained.

Design outcomes

Primary

Measure	Time frame
The primary endpoint is diagnostic accuracy to distinguish undifferentiated- from differentiated-type early gastric cancer.	—

Secondary

Measure	Time frame
The key secondary endpoint is specificity to distinguish undifferentiated- from differentiated-type early gastric cancer.	—

Countries

Japan

Contacts

Public ContactTakashi Kanesaka

Osaka International Cancer Institute Department of Gastrointestinal Oncology

takashikanesaka@gmail.com06-6945-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026